An Open-Label, Dose-Escalation Phase 1/1b Study of the Anti-gp75 Monoclonal Antibody IMC-20D7S In Patients With Malignant Melanoma Who Have Progressed After or During at Least One Treatment With Standard Cytotoxic Treatment or/and Immunotherapy Therapy or For Whom Standard Therapy is Not Indicated.

Trial Profile

An Open-Label, Dose-Escalation Phase 1/1b Study of the Anti-gp75 Monoclonal Antibody IMC-20D7S In Patients With Malignant Melanoma Who Have Progressed After or During at Least One Treatment With Standard Cytotoxic Treatment or/and Immunotherapy Therapy or For Whom Standard Therapy is Not Indicated.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Flanvotumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors ImClone Systems
  • Most Recent Events

    • 01 Nov 2016 Results assessing safety, efficacy and pharmacokinetics published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 19 Oct 2016 Results analysing safety and efficacy published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top